MAXHEALTH - Max Healthcare Institute Limited Share Price

In the earnings call held on February 6, 2026, Max Healthcare's management provided an optimistic outlook, citing a 21st consecutive quarter of year-on-year revenue growth. Key highlights include a 10% increase in revenue to INR 2,608 crore in Q3 FY '26, while operating EBITDA grew by 4% to INR 648 crore, resulting in an EBITDA margin of 26.1%. The company is positioned for continued growth, given that cashless services have been fully restored, with expected upward revisions in CGHS tariffs set to commence by April 2026.

Major forward-looking points shared include:

1. Capacity Expansion: The addition of new brownfield beds is expected to drive EBITDA and margin accretion. A total of 63 brownfield beds were commissioned at Nanavati Max, and 53 beds at Max Mohali are anticipated to ramp up by Q4 FY '26. Furthermore, Max is developing a 450-bed hospital in Pune expected to be operational by 2030.

2. Operational Metrics: The average occupancy rate stood at 74% with 7% growth in occupied bed days, despite challenges regarding seasonal demand. Average Revenue Per Occupied Bed (ARPOB) was reported at INR 77,900, a modest growth of 3% year-on-year, indicating sustained revenue per patient.

3. Digital Initiatives: Digital revenue surged to INR 803 crore, representing 31% of total revenue with significant website engagement at 71 lakh sessions, signaling successful online marketing efforts.

4. Debt Position: The company's net debt reached INR 2,166 crore, maintaining a net debt-to-EBITDA ratio of under 1. Cash flow generation for the quarter was INR 281 crore, highlighting effective operational cash management against a backdrop of ongoing capacity investments.

5. Community Support: The firm provided free treatment worth INR 61 crore to approximately 40,000 economically weaker patients, showcasing its commitment to CSR.

Overall, management expressed confidence in navigating future challenges while continuing to expand its service network and enhance financial performance.

Question: "Do you think you can go back to the prior level of contribution from oncology? And what could drive it back?"
Answer: The oncology contribution drop is linked to high-value drugs, which had low margins despite their revenue significance. We believe there will be a recovery in contribution as we engage with CGHS, pushing for necessary tariff adjustments. As institutional shifts stabilize and as discussions with CGHS progress, we expect oncology's revenue contribution to improve, though it may take time.

Question: "Has the oncology team fully recovered in strength? What kind of further pickup can we see in oncology?"
Answer: Any team departures are swiftly compensated by hiring similarly qualified professionals. Recently, we've strengthened our team with highly qualified individuals from our competitors. Therefore, while some transitions occur, we are well-positioned to sustain and enhance our oncology capabilities moving forward.

Question: "Have you renewed all the insurance contracts? Is there anything pending?"
Answer: The recent quarter saw disruptions in renewals, leading to numerous complaints. However, we restored these services, and now have a mechanism for annual pre-agreed increments in contracts to avoid future issues. This addresses past delays and ensures smoother renewals moving forward. So, anything pending has been resolved.

Question: "What kind of increment can we expect from insurance this year?"
Answer: While specific numbers are hard to pin down, we did secure a moderate upward revision in rates across our insured patients. This increment does not adversely affect our financials and aligns well with historical adjustments, suggesting that revenue growth will continue without significant disruptions.

Question: "What is the expected path for institutional patients or concerns regarding other insurers?"
Answer: Institutional patient volume has increased due to our strategies amid the disruption. While there could be waves of negotiations with insurance partners, recent events have led to lessons learned across the industry, ideally softening future negotiations and potentially stabilizing our patient base in this category.

Question: "Can you elaborate on the EBITDA contribution from new facilities?"
Answer: New facilities like Nanavati and Saket have shown quick operational breakeven with margins remaining solid. As we increase capacity, the cash flow generated is expected to be margin-accretive. Our strategy ensures that we leverage operating leverage, leading to improved profitability as these facilities ramp up operations.

Question: "What is guidance on hospital commission dates?"
Answer: We expect to commission the first phase of the new Gurgaon facility by the end of H1 FY '27. While specific guidance on potential losses isn't available, historical performance suggests that strong patient demand can lead to quicker breakeven, mitigating loss duration.

Question: "Clarify the CGHS revenue impact and how it is split?"
Answer: The projected INR 200 crore revenue uplift accounts for rate revisions minus losses from discontinued oncology drugs due to CGHS pricing. A portion of this will be negated by the impact of GST, so we anticipate a sustained net impact of around INR 140 crore moving forward.

Question: "What is the anticipated bedroom capacity growth over the years?"
Answer: Currently, we operate around 4,800 beds and plan to reach approximately 6,000 by FY '28, with ongoing expansions and new facilities in the pipeline. The eventual goal is to have around 8,000 operational beds by FY '28, aligning with our overall strategic growth objectives.